Eli Lilly Launches Open Letter about Mounjaro® and Zepbound® Use
Lilly's Open Letter on Tirzepatide Medicines: Mounjaro and Zepbound should not be used for cosmetic weight loss. Patient safety is top priority.
Gastrointestinal disease News & Breaking Stories
Teen with Sanfilippo Syndrome: Meet Logan Pacl, AKA Childhood Alzheimer's
A mother shares her son's journey with Sanfilippo Syndrome, also known as 'childhood Alzheimer's,' and the challenges and joys they experience daily.
U.S. FDA Approves New Version of Diabetes Drug Mounjaro for Weight Loss
New diabetes drug Zepbound, also known as tirzepatide, can be sold as a weight-loss drug, helping dieters lose 40-60 pounds.
Get Weekly News Updates
Subscribe to SHUT Newsletter and be up to date with the current events. Be informed, don't settle for fake news.